Interventions to improve the mental health of children and young people with long-term physical conditions: linked evidence syntheses (Health Technology Assessment) Although this study showed that CBT may be beneficial for some young people with long-term conditions, the evidence is limited. https://www.journalslibrary.nihr.ac.uk/hta/hta23220/#/abstract Exercise-based cardiac rehabilitation for chronic heart failure: the EXTRAMATCH II individual participant data meta-analysis (Health Technology Assessment) Exercise-based cardiac rehabilitation improved exercise capacity and health-related quality of life in people with heart failure regardless of severity, age and gender, but had no effect on mortality or hospitalisation. https://www.journalslibrary.nihr.ac.uk/hta/hta23250/#/abstract
http://www.healthscotland.scot/publications/rapid-systematic-literature-review-impact-of-inpremise-marketing-on-consumer-purchasing-and-consumption
NICE -Guidelines

Hypertension in pregnancy: diagnosis and management [NG133]
Covers diagnosing and managing hypertension (high blood pressure), including pre-eclampsia, during pregnancy, labour and birth. Includes advice for women with hypertension who wish to conceive and women who have had a pregnancy complicated by hypertension. It aims to improve care during pregnancy, labour and birth for women and their babies. https://www.nice.org.uk/guidance/ng133
Depression in children and young people: identification and management [NG134]
Covers identifying and managing depression in children and young people aged 5 to 18 years. Based on the stepped-care model, it aims to improve recognition and assessment and promote effective treatments for mild and moderate to severe depression. includes new and updated recommendations on psychological therapies for mild depression and psychological therapies for moderate to severe depression https://www.nice.org.uk/guidance/ng134
NICE -Technology Appraisal guidance
Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes [TA583] Ertugliflozin with metformin and a dipeptidyl peptidase 4 (DPP 4) inhibitor is recommended as an option for treating type 2 diabetes in adults when diet and exercise alone do not provide adequate glycaemic control, only if the disease is uncontrolled with metformin and a DPP 4 inhibitor, and a sulfonylurea or pioglitazone is not appropriate. https://www.nice.org.uk/guidance/ta583 Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer [TA584] Atezolizumab plus bevacizumab, carboplatin and paclitaxel is recommended as an option for metastatic non-squamous non-small-cell lung cancer (NSCLC) in adults who have not had treatment for their metastatic NSCLC before and whose PD-L1 tumour proportion score is between 0% and 49% or when targeted therapy for epidermal growth factor receptor (EGFR) positive or anaplastic lymphoma kinase (ALK) positive NSCLC has failed. It is recommended only if atezolizumab and bevacizumab are stopped at 2 years of uninterrupted treatment, or earlier if there is loss of clinical benefit (for atezolizumab) or if the disease progresses (for bevacizumab).
Ocrelizumab for treating primary progressive multiple sclerosis [TA585]
Ocrelizumab is recommended as an option for treating early primary progressive multiple sclerosis with imaging features characteristic of inflammatory activity in adults. https://www.nice.org.uk/guidance/ta585/chapter/1-Recommendations Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib [TA586] Lenalidomide plus dexamethasone is recommended as an option for treating multiple myeloma in adults only if they have had only one previous therapy, which included bortezomib. https://www.nice.org.uk/guidance/ta586
Lenalidomide plus dexamethasone for previously untreated multiple myeloma [TA587]
Lenalidomide plus dexamethasone is recommended as an option for previously untreated multiple myeloma in adults who are not eligible for a stem cell transplant, only if thalidomide is contraindicated (including for pre-existing conditions that it may aggravate) or the person cannot tolerate thalidomide. https://www.nice.org.uk/guidance/ta587
EPPI Centre
Nil
AHRQ (Agency for Healthcare Research and Quality -USA)
Management of Infertility (systematic review) The ability to compare the effectiveness of treatments would be enhanced by greater consistency in reporting of outcomes, particularly live birth rates, as well as reporting of diagnosis specific outcomes for treatments, such as assisted reproductive technology, that are used for multiple diagnoses. Letrozole most likely results in more live births with lower multiple births than clomiphene alone in women with polycystic ovary syndrome. For women with unexplained infertility, there is most likely shorter time to pregnancy for women with immediate in vitro fertilization (IVF) than for those who undergo other treatments prior to IVF. For the outcomes of live birth, multiple births, ectopic pregnancy, miscarriage, low birthweight, and ovarian hyperstimulation syndrome however, there may be no difference between the two groups.. Across all diagnoses, elective single-embryo transfer results in slightly lower live birth rates but substantially lower reductions in multiple birth rates than multiple-embryo transfer. https://effectivehealthcare.ahrq.gov/topics/infertility/research
Health Foundation
Untapped potential: Investing in health and care data analytics (report) Investment is needed to unlock the full potential of data and support its use in clinical decisionmaking, innovation and change, the evaluation of new models of care, effective board-level oversight of complex care systems, better everyday management of the monitoring and improvement of the quality and efficiency of care and in providing better responses to national incentives and regulation, resource allocation etc. https://www.health.org.uk/sites/default/files/upload/publications/2019/Untapped%20potential.pdf
Canadian Agency for drugs and Technologies in Health (CADTH) Room Service Food Delivery Models for Hospital In-Patients: Perspectives and Experiences (Rapid response)
Alternative food delivery models have the potential to increase patient satisfaction when compared to traditional meal delivery service. Patient satisfaction is influenced not just by the quality of the food but also by presentation and delivery. Choice of meal options and flexibility in meal delivery times were crucial components of satisfaction for both patients and hospital personnel. Offering a variety of food choices may increase food intake and nutritional status, with options available that are more in line with individual patient's preferences, personalized eating habits and culinary practices. Choice also gives patients some comfort and control in an otherwise regimented environment. For hospital personnel, not having the ability to individualize meals for patients, or offer snacks between meals, is perceived as a barrier to meeting patients' nutritional needs. Hospital staff additionally raised concerns about the food budget and outsourcing of food as reasons for the lack of variety in food choices. Flexible meal times can have key clinical benefits for patients who would otherwise miss or skip meals, or not eat all of the food delivered to them. https://www.cadth.ca/room-service-food-delivery-models-hospital-patients-perspectives-andexperiences
Room Service Food Delivery Models for Hospital In-Patients: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines (Rapid response)
Evidence of limited quality demonstrated that food delivery models that provided patients with increased flexibility in meal options and timing of meal delivery generally improved the nutritional intake of hospital in-patients but there was no literature identified that suggested these increases in nutritional intake translated to decreased hospital length of stay. It was unclear which specific food delivery models may be most beneficial to in-patients (e.g., pre-plated service, communal dining halls, spoken menus or other electronic ordering systems, chilled kitchens, steamplicity systems, or on-demand dining). No evidence regarding the cost-effectiveness of alternative room service food delivery models for hospital in-patients was identified. The limitations of the included studies (e.g., their open-label nature, the severe risk of bias due to confounding) and of this report should be considered when interpreting the results. https://www.cadth.ca/room-service-food-delivery-models-hospital-patients-review-clinicaleffectiveness-cost-effectiveness
Immune Checkpoint Inhibitors for Classical Hodgkin Lymphoma in Brentuximab Vedotin-naïve Patients: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines (Rapid Response)
Evidence on the treatment of Hodgkin Lyphoma in brentuximab vedotin-naïve patients with immune checkpoint inhibitors is sparse. One set of evidence-based guidelines (from the USA) provided recommendations on diagnosing, treating, and following patients with early stage, intermediate stage, or advanced stage classical Hodgkin lymphoma. Based on evidence of limited quality, the guidelines recommend treating eligible adults with immune checkpoint inhibitors such as nivolumab and pembrolizumab for relapsed or refractory Hodgkin lymphoma following autologous hematopoietic stem cell transplantation with or without brentuximab vedotin. The recommendation was not specific to brentuximab vedotin-naïve patients and sections of the guideline document remain under development. The guidelines indicated that immune checkpoint inhibitors may be considered as an option for patients who are ineligible for stem cell transplantation due to comorbidity or failed second-line chemotherapy. Nivolumab and pembrolizumab may also be used for patients following allogeneic stem cell transplantation. Guidance was provided suggesting that nivolumab and pembrolizumab may be offered as palliative therapy options for patients older than 60 years who were previously treated with brentuximab vedotin. https://www.cadth.ca/immune-checkpoint-inhibitors-classical-hodgkin-lymphoma-brentuximabvedotin-naive-patients-review Laser Interstitial Thermal Therapy for Epilepsy and/or Brain Tumours: A Review of Clinical Effectiveness and Cost-Effectiveness (Rapid response) Should be read with caution as some studies were financially-sponsored by the manufacturer of one of the LITT systems and the lists of authors included consultants employed by the company. Limited evidence suggested that LITT proffers no advantage over stereotactic radiosurgery in inducing seizure freedom in patients with drug-resistant, medically-intractable temporal lobe epilepsy. Relative to patients who were treated with stereotactic radiosurgery and craniotomy, patients treated with LITT appeared to experience fewer adverse events and complications. No comparative evidence on disease progression, overall survival, hospitalization, or quality of life was found. None of the studies reported on the incidence of epileptic episodes, post-operative pain, use of medication, or hospital readmissions. LITT was cost-effective relative to a combination of craniotomy
